Inventiva (NASDAQ:IVA - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $13.00 target price on the stock. HC Wainwright's price target indicates a potential upside of 428.24% from the stock's previous close.
A number of other equities research analysts have also issued reports on the stock. Stifel Nicolaus cut their price target on shares of Inventiva from $20.00 to $17.00 and set a "buy" rating on the stock in a report on Friday, November 22nd. UBS Group assumed coverage on shares of Inventiva in a research note on Tuesday, November 12th. They issued a "neutral" rating and a $3.00 price objective on the stock.
Read Our Latest Report on IVA
Inventiva Trading Up 1.7 %
Inventiva stock traded up $0.04 during mid-day trading on Thursday, hitting $2.46. The company's stock had a trading volume of 10,438 shares, compared to its average volume of 9,427. Inventiva has a twelve month low of $1.53 and a twelve month high of $4.50. The stock's fifty day moving average price is $2.36 and its two-hundred day moving average price is $2.35.
Inventiva Company Profile
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Stories
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
